Arbutus Biopharma Company Insiders
| ABUS Stock | USD 3.42 0.09 2.56% |
Arbutus Biopharma employs about 73 people. The company is managed by 11 executives with a total tenure of roughly 171 years, averaging almost 15.0 years of service per executive, having 6.64 employees per reported executive. Breaking down Arbutus Biopharma's management performance can provide insight into the firm performance.
Arbutus |
Arbutus Biopharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Arbutus Biopharma's future performance. Based on our forecasts, it is anticipated that Arbutus will maintain a workforce of slightly above 70 employees by December 2024.Arbutus Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3283) % which means that it has lost $0.3283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6781) %, meaning that it created substantial loss on money invested by shareholders. Arbutus Biopharma's management efficiency ratios could be used to measure how well Arbutus Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2024. Return On Capital Employed is likely to drop to -0.67 in 2024. At this time, Arbutus Biopharma's Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 165.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.8 M in 2024.Common Stock Shares Outstanding is likely to gain to about 174.3 M in 2024, whereas Net Loss is likely to drop (65.6 M) in 2024.
Arbutus Biopharma Workforce Comparison
Arbutus Biopharma Corp is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,381. Arbutus Biopharma holds roughly 73.0 in number of employees claiming about 5% of equities under Health Care industry.
Arbutus Biopharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arbutus Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arbutus Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arbutus Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 0.5 | 1 | 2 | 54,915 | 63,761 |
| 2024-03-01 | 2.5 | 10 | 4 | 2,709,200 | 34,097 |
| 2023-09-01 | 0.375 | 3 | 8 | 763,640 | 288,560 |
| 2021-12-01 | 1.0 | 2 | 2 | 22,877,922 | 1,364,000 |
| 2021-03-01 | 6.0 | 6 | 1 | 1,914,000 | 20,000 |
| 2020-09-01 | 2.0 | 2 | 1 | 120,000 | 20,000 |
| 2018-12-01 | 1.5 | 6 | 4 | 364,500 | 91,268 |
| 2018-06-01 | 12.0 | 12 | 1 | 1,120,194 | 27,007 |
| 2018-03-01 | 8.0 | 8 | 1 | 5,312,000 | 0.00 |
| 2017-12-01 | 8.0 | 8 | 1 | 4,000,000 | 10,000 |
| 2017-03-01 | 7.0 | 7 | 1 | 1,150,000 | 15,000 |
| 2016-06-01 | 6.0 | 6 | 1 | 42,500 | 5,000 |
| 2015-09-01 | 2.8 | 14 | 5 | 694,972 | 341,472 |
| 2015-03-01 | 0.2941 | 5 | 17 | 340,000 | 184,915 |
Arbutus Biopharma Notable Stakeholders
An Arbutus Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arbutus Biopharma often face trade-offs trying to please all of them. Arbutus Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arbutus Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael McElhaugh | Interim CoFounder | Profile | |
| BA Esq | General Officer | Profile | |
| Gaston Picchio | Chief Officer | Profile | |
| Lisa Caperelli | Vice Relations | Profile | |
| David CPA | CFO Officer | Profile | |
| William Collier | CEO Pres | Profile | |
| Elizabeth Howard | Gen VP | Profile | |
| Michael Sofia | Chief Officer | Profile | |
| BA JD | Sec | Profile | |
| Karen MD | Chief Officer | Profile | |
| Shannon SPHR | Vice Resources | Profile |
About Arbutus Biopharma Management Performance
The success or failure of an entity such as Arbutus Biopharma Corp often depends on how effective the management is. Arbutus Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arbutus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arbutus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.64) | (0.67) | |
| Return On Assets | (0.50) | (0.53) | |
| Return On Equity | (0.69) | (0.65) |
Please note, the imprecision that can be found in Arbutus Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arbutus Biopharma Corp. Check Arbutus Biopharma's Beneish M Score to see the likelihood of Arbutus Biopharma's management manipulating its earnings.
Arbutus Biopharma Workforce Analysis
Traditionally, organizations such as Arbutus Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arbutus Biopharma within its industry.Arbutus Biopharma Manpower Efficiency
Return on Arbutus Biopharma Manpower
| Revenue Per Employee | 248.5K | |
| Revenue Per Executive | 1.6M | |
| Net Loss Per Employee | 997.9K | |
| Net Loss Per Executive | 6.6M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 10M |
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.